DNA vaccination with all-trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4+ and CD8+ T-cell activation in an acute promyelocytic leukemia mouse model

Blood. 2010 Jan 21;115(3):653-6. doi: 10.1182/blood-2007-08-109009. Epub 2009 Nov 19.

Abstract

DNA vaccination and all-trans retinoic acid (ATRA) result in a survival advantage in a mouse model of acute promyelocytic leukemia (APL). Depletion of CD4(+) or CD8(+) cells abolished this effect. CD4(+) depletions of long-term survivors resulted in relapse and death within 3 months, thus demonstrating the need of both CD4(+) and CD8(+) subsets for the generation of DNA-driven antileukemic immune responses and underscoring a crucial role of CD4(+) cells in the maintenance of durable remissions. Degranulation and cytotoxic carboxyfluorescein diacetate succinimidyl ester-based assays showed major histocompatibility complex-restricted APL-specific T cell-mediated immune responses. Sorted APL-specific CD8(+)CD107a(+) T cells showed an increase of antileukemic activity. Effectors from ATRA + DNA-treated mice were shown to secrete interferon-gamma when stimulated with either APL cells or peptides from the promyelocytic leukemia-RARalpha vaccine-derived sequences as detected by ELISpot assays. Our results demonstrate that DNA vaccination with ATRA confers the effective boosting of interferon-gamma-producing and cytotoxic T cells in the leukemic mice.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CD4-Positive T-Lymphocytes / drug effects
  • CD4-Positive T-Lymphocytes / immunology*
  • CD4-Positive T-Lymphocytes / metabolism
  • CD4-Positive T-Lymphocytes / pathology
  • CD8-Positive T-Lymphocytes / drug effects
  • CD8-Positive T-Lymphocytes / immunology*
  • CD8-Positive T-Lymphocytes / metabolism
  • CD8-Positive T-Lymphocytes / pathology
  • Combined Modality Therapy
  • Disease Models, Animal
  • Humans
  • Immunity, Cellular* / drug effects
  • Immunity, Cellular* / genetics
  • Leukemia, Promyelocytic, Acute / immunology
  • Leukemia, Promyelocytic, Acute / pathology
  • Leukemia, Promyelocytic, Acute / therapy*
  • Lymphocyte Activation / drug effects
  • Lymphocyte Activation / genetics
  • Mice
  • Oncogene Proteins, Fusion / administration & dosage
  • Oncogene Proteins, Fusion / genetics
  • Survival Analysis
  • Treatment Outcome
  • Tretinoin / administration & dosage*
  • Tumor Cells, Cultured
  • Vaccines, DNA / administration & dosage*
  • Vaccines, DNA / metabolism
  • Xenograft Model Antitumor Assays

Substances

  • Oncogene Proteins, Fusion
  • Vaccines, DNA
  • promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
  • Tretinoin